Research Development Foundation is an American private company that operates as noncommercial research organizations.

Develops and manufactures drugs related to immunology, neurobiology and oncology

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Consiglio Nazionale delle Ricerche is the largest public research facility in Italy. Founded in 1923, it has worked in the past as a government consultant on research and as a funding fund for university research grants. Since 1989 the CNR is a research institution, with the mission of carrying out research projects, promoting innovation and competitiveness of the national industrial system, the internationalization of the national research system, and providing technologies and solutions to emerging needs in the public and private sectors. . Objectives that are achieved through a wealth of human resources that has over 8000 employees, half of which is represented by researchers and technologists. About 4,000 young researchers are involved in post-doctoral research activities in the laboratories of the Institute, while an important contribution comes from collaborations, including international ones, with researchers from universities and companies, thus strengthening the national research system.

Austin Research Institute is an Australian private company located in Heidelberg that conducts medical research.

Nucleus Biologics LLC develops cellular immunotherapies. Its products include PhysiologixTM XF SR, Vitronectin XF, Australia and New Zealand Origin FBS and zIsletTM media. The firm offers complete media manufacturing services. The company was founded in 2016 and is headquartered in San Diego, CA.

Hangzhou Xinruijia Biomedical Technology Development Co., Ltd., established on 2002-07-23, The scope of business includes new medical technology,Research and development of new products and health care products(Except for products prohibited and restricted by the state).***

Primorigen Biosciences, Inc. operates as a research and manufacturing company. Its versatile coated microcarrier platform provided superior cell proliferation and seeding efficiency in customer trials while reducing preparation from multiple days to minutes. The company was founded by Charles Oehler and Thomas J. Burke in 2005 and is headquartered in Madison, WI.

DeWitt Ross & Stevens is a private company headquartered in Madison, WI, that provides legal services.\nThe company says this about itself: DeWitt Ross & Stevens S.C., including its affiliate DeWitt Mackall Crounse & Moore S.C., is one of the ten largest law firms based in Wisconsin, with an additional presence in Minnesota. It has nearly 140 attorneys practicing in Madison and Metropolitan Milwaukee, Wisconsin and Minneapolis, Minnesota, in a variety of legal areas and has the experience to service clients of all scopes and sizes. The firm is known for its work in several areas, including construction, products liability, civil rights litigation, corporate law, employment, environmental, employee benefits, estate planning, family law, government relations, health care, intellectual property, patents, trademarks and copyright law, litigation, personal injury, real estate, and tax law.

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.